{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:30:47Z","timestamp":1762101047897,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T00:00:00Z","timestamp":1282176000000},"content-version":"vor","delay-in-days":58,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Nilotinib is active in imatinib\u2010resistant and \u2010intolerant chronic myeloid leukemia patients and was recently approved for these indications.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials with similar designs (CAMN107AIL01 and ENACT).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of 88 study patients (58 chronic, 11 accelerated, 19 blast crisis), the best responses to nilotinib were complete hematologic response (CHR) in 27%, partial cytogenetic response in 12%, complete cytogenetic response in 14%, and major molecular response in 19%. Patients achieving at least a CHR during imatinib therapy were more likely to respond to nilotinib, and failure to achieve at least a CHR on imatinib therapy was predictive of progression or lack of response to nilotinib (<jats:italic>P<\/jats:italic> = .0021). Responses were not statistically different in subgroup analysis, including that of imatinib intolerance compared with imatinib resistance, presence of ABL kinase domain mutations compared with absence of mutations, and previous treatment with another second\u2010generation tyrosine kinase inhibitor compared no prior treatment. The overall survival and progression\u2010free survival rates at 1 year were 83% and 48% for the entire cohort, 93% and 66% in chronic phase, and 64% and 19% in advanced phase. Adverse hematological events included thrombocytopenia (all events, 27%; grade 3\u20104, 13%) and leukopenia (all events, 18%; grade 3\u20104, 10%). The majority of the nonhematological events were mild, the most common being rash, infection, bone pain, headache, nausea, and vomiting.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Nilotinib treatment is an efficient and safe therapy for imatinib\u2010resistant or \u2010intolerant patients. Prior response to imatinib therapy is a predictor for the response to nilotinib. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25351","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T10:11:42Z","timestamp":1277201502000},"page":"4564-4572","source":"Crossref","is-referenced-by-count":16,"title":["Activity and tolerability of nilotinib"],"prefix":"10.1002","volume":"116","author":[{"given":"Maya","family":"Koren\u2010Michowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Prejzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neta","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.1038\/leu.2009.38"},{"doi-asserted-by":"publisher","key":"e_1_2_6_3_2","DOI":"10.1038\/sj.leu.2402741"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1182\/blood-2005-12-010132"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_2","DOI":"10.1182\/blood-2007-03-080689"},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_2","DOI":"10.1182\/blood-2007-04-083196"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_2","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/jco.2008.26.15_suppl.7017","article-title":"Nilotinib in patients with Philadelphia chromosome\u2010positive chronic myelogenous leukemia in blast crisis (CML\u2010BC) who are resistant or intolerant to imatinib","volume":"26","author":"Giles FJ","year":"2008","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_2","DOI":"10.1158\/1078-0432.CCR-08-0308"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_2","DOI":"10.1182\/blood-2007-03-066936"},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_2","DOI":"10.1038\/sj.leu.2404635"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_2","DOI":"10.1056\/NEJMoa022457"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1182\/blood.V99.6.1928"},{"doi-asserted-by":"publisher","key":"e_1_2_6_15_2","DOI":"10.1182\/blood.V99.10.3530"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_2","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_2_6_17_2","first-page":"3229","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML\u2010AP) with imatinib resistance or intolerance: 2\u2010year follow\u2010up results of a phase 2 study [abstract]","volume":"112","author":"le Coutre PD","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_6_18_2","first-page":"3238","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2\u2010year follow\u2010up results of a phase 2 study [abstract]","volume":"112","author":"Kantarjian HM","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_6_19_2","first-page":"3234","article-title":"Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML\u2010chronic phase) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]","volume":"112","author":"Giles F","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_6_20_2","first-page":"331","article-title":"The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]","volume":"112","author":"Branford S","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_2","DOI":"10.1182\/blood-2008-10-184960"},{"key":"e_1_2_6_22_2","first-page":"3216","article-title":"Nilotinib efficacy according to baseline BCR\u2010ABL mutations in patients with imatinib\u2010resistant chronic myeloid leukemia in chronic phase (CML\u2010CP) [abstract]","volume":"112","author":"Hochhaus A","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_2","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_2","DOI":"10.1182\/blood-2006-01-015347"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_2","DOI":"10.1200\/JCO.2008.19.8853"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_2","DOI":"10.1016\/j.ccr.2005.01.007"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25351","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:12:19Z","timestamp":1760285539000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25351"}},"subtitle":["A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant"],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/cncr.25351"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25351","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}